| Stacy L Greenspan, DO | |
|
2912 Cathedral Park Vw, Colorado Springs, CO 80904-4722 | |
| (952) 595-1100 | |
| (612) 294-4903 |
| Full Name | Stacy L Greenspan |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 34 Years |
| Location | 2912 Cathedral Park Vw, Colorado Springs, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336124825 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Havasu Regional Medical Center | Lake havasu city, AZ | Hospital |
| Paris Regional Medical Center | Paris, TX | Hospital |
| Mountain View Regional Medical Center | Las cruces, NM | Hospital |
| Duncan Regional Hospital, Inc | Duncan, OK | Hospital |
| Banner Boswell Medical Center | Sun city, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Singleton Associates Pa | 6305731118 | 691 |
| Eagle Partners Pllc | 9032205752 | 92 |
| Singleton Associates Pa | 6305731118 | 691 |
| Sonoran Radiology Ltd | 3375964505 | 367 |
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Singleton Associates Pa | 6305731118 | 691 |
| Eagle Partners Pllc | 9032205752 | 92 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Diversified Radiology Of Colorado Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205923596 PECOS PAC ID: 0143132316 Enrollment ID: O20031105000319 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Radiology & Imaging Consultants, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598700825 PECOS PAC ID: 1850298647 Enrollment ID: O20031218000702 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Radadvantage A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376719666 PECOS PAC ID: 2163597899 Enrollment ID: O20090304000478 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Uch-mhs |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083967988 PECOS PAC ID: 4486803426 Enrollment ID: O20121025000367 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Radiology Alliance Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861478489 PECOS PAC ID: 1850280470 Enrollment ID: O20130917000215 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Eagle Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548450976 PECOS PAC ID: 9032205752 Enrollment ID: O20140819001131 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Southwest Diagnostic Imaging Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902896236 PECOS PAC ID: 7416946199 Enrollment ID: O20150518001399 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Central Illinois Radiological Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538192828 PECOS PAC ID: 9436061827 Enrollment ID: O20160107001449 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Spectrum Medical Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164881652 PECOS PAC ID: 1355647595 Enrollment ID: O20160314001910 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20170424001230 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Columbus Radiology Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669408159 PECOS PAC ID: 6507754983 Enrollment ID: O20170630001497 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Orthopedic Centers Of Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801339502 PECOS PAC ID: 2365714540 Enrollment ID: O20170823001317 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Coastal Radiology Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144270307 PECOS PAC ID: 8224002696 Enrollment ID: O20171013001298 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Imaging Associates Of New Mexico Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629592464 PECOS PAC ID: 4981970233 Enrollment ID: O20180312001062 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Specialists In Medical Imaging Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841687951 PECOS PAC ID: 2163733544 Enrollment ID: O20180426000954 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Radiology Affiliates Of Central New Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811994791 PECOS PAC ID: 1759277239 Enrollment ID: O20190215001277 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Renaissance Imaging Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487608931 PECOS PAC ID: 7315841756 Enrollment ID: O20190403001161 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20190711001859 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Quantum Medical Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164475869 PECOS PAC ID: 3577468040 Enrollment ID: O20190826002920 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Empire State Radiology P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255962783 PECOS PAC ID: 4385075241 Enrollment ID: O20200512003474 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Entity Name | Greensboro Radiology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821035999 PECOS PAC ID: 8729074901 Enrollment ID: O20200729002256 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stacy L Greenspan, DO 11995 Singletree Ln, Suite 500, Eden Prairie, MN 55344-5347 Ph: (952) 595-1301 | Stacy L Greenspan, DO 2912 Cathedral Park Vw, Colorado Springs, CO 80904-4722 Ph: (952) 595-1100 |
News Archive
Many research studies have made it clear that a mother's eating habits prior to pregnancy, during pregnancy and during lactation have a profound impact on her offspring and their propensity for developing weight problems, including obesity.
Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.
Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.
A computer simulation breakthrough could mean fewer medical complications and better surgical outcomes for patients undergoing hip, knee or spinal implant surgery.
› Verified 7 days ago
Dr. Courtney Todd Tripp, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 3050 Richfield Dr, Colorado Springs, CO 80919 Phone: 719-445-2282 | |
Dr. Fahim Hashmi, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2222 N Nevada Ave, Colorado Springs, CO 80907 Phone: 516-562-0100 | |
Dr. Barry Lee Gardner, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1644 Medical Center Pt, Suite 100, Colorado Springs, CO 80907 Phone: 719-247-5500 Fax: 719-247-5437 | |
Dr. John B Campbell, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2222 N Nevada Ave, Colorado Springs, CO 80907 Phone: 719-593-1799 Fax: 719-265-3794 | |
Dr. Jon F Snider, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2222 N Nevada Ave, Colorado Springs, CO 80907 Phone: 719-593-1799 Fax: 719-265-3794 | |
John L Sherman, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 69 W Boulder St, Colorado Springs, CO 80903 Phone: 719-389-1106 Fax: 719-389-1180 | |
Dr. John E Schiller, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2222 N Nevada Ave, Suite 101, Colorado Springs, CO 80907 Phone: 719-776-5281 Fax: 719-471-9314 |